14 results on '"W. Knauf"'
Search Results
2. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
- Author
-
Knauf W, Abenhardt W, Koenigsmann M, Maintz C, Sandner R, Zahn MO, Schnell R, Tech S, Kaiser-Osterhues A, Houet L, and Marschner N
- Subjects
- Aged, Bendamustine Hydrochloride administration & dosage, Disease-Free Survival, Female, Germany epidemiology, Humans, Male, Middle Aged, Prospective Studies, Rituximab administration & dosage, Survival Rate, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Lymphoma, B-Cell, Marginal Zone drug therapy, Lymphoma, B-Cell, Marginal Zone mortality, Registries
- Abstract
Owing to its heterogeneity and rarity, management of disseminated marginal zone B-cell lymphoma (MZL) remains largely understudied. We present prospective data on choice of systemic treatment and survival of patients with MZL treated in German routine practice. Of 175 patients with MZL who had been documented in the prospective clinical cohort study Tumour Registry Lymphatic Neoplasms (NCT00889798) collecting data on systemic treatment, 58 were classified as extranodal MZL of mucosa-associated lymphoid tissue (MALT) and 117 as non-MALT MZL. We analyzed the most commonly used first-line and second-line chemo(immuno)therapies between 2009 and 2016 and examined objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and prognostic factors for survival. Compared to patients with MALT MZL, those with non-MALT MZL more often presented with bone marrow involvement (43% vs. 14%), Ann Arbor stage III/IV (72% vs. 57%) and were slightly less often in good general condition (ECOG = 0; 41% vs. 47%). In German routine practice, rituximab-bendamustine for a median of 6 cycles was the most frequently used first-line (76%) and second-line treatment (36%), with no major differences between MZL subtypes. The ORR for patients encompassing any positive response was 81%. For patients with MALT and non-MALT MZL, respectively, 5-years PFS was 69% (95% CI 52%-81%) and 66% (95% CI 56%-75%), 5-years OS 79% (95% CI 65%-89%) and 75% (95% CI 66%-83%). Cox proportional hazards models showed a significantly increased risk of mortality for higher age in all patient groups. Our prospective real world data give valuable insights into the management and outcome of non-selected patients with MZL requiring systemic treatment and can help optimize therapy recommendations., (© 2021 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
3. Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms.
- Author
-
Knauf W, Abenhardt W, Slawik HR, Bückner U, Otremba B, Sauer A, Zahn MO, Wetzel N, Kaiser-Osterhues A, Houet L, and Marschner N
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Prognosis, Retrospective Studies, Survival Rate, Waldenstrom Macroglobulinemia pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Waldenstrom Macroglobulinemia drug therapy, Waldenstrom Macroglobulinemia mortality
- Abstract
Waldenström's macroglobulinaemia (WM) is a rare indolent B-cell lymphoma for which only little prospective phase III evidence exists. Thus, real world data are important to provide insight into treatment and survival. We present here data on choice and outcome of systemic treatment of patients with WM treated in German routine practice. In total, 139 patients with WM who had been documented in the prospective clinical cohort study Tumour Registry Lymphatic Neoplasms (NCT00889798) were included into this analysis. We analysed the most frequently used first-line and second-line treatments between 2009 and 2017 and examined best response, progression-free survival (PFS) and overall survival (OS). Bendamustine plus rituximab, with a median of six cycles, was by far the most frequently used first-line treatment (81%). Second-line treatment was more heterogenous and mainly based on bendamustine, cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP), fludarabine or ibrutinib, the latter approved in 2014. Three-year PFS from start of first-line treatment was 83% (95% confidence interval [CI] 74%-88%), 3-year OS was 87% (95% CI 80%-92%). These prospective data give valuable insights into the management and outcome of non-selected patients with WM treated in German routine practice. In the lack of prospective phase III clinical trials, real world data can help bridging the gap of evidence., (© 2020 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
4. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2 nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
- Author
-
Mey UJ, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna CJ, Schmid M, Schmidt-Hieber M, Doerfel S, Fischer N, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, and Driessen C
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bendamustine Hydrochloride adverse effects, Dexamethasone administration & dosage, Humans, Lenalidomide, Middle Aged, Multiple Myeloma complications, Neutropenia chemically induced, Remission Induction methods, Thalidomide administration & dosage, Thalidomide analogs & derivatives, Thrombocytopenia chemically induced, Thrombocytopenia complications, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Multiple Myeloma drug therapy, Salvage Therapy methods
- Abstract
The combination of lenalidomide (Revlimid
® , R) and dexamethasone (d) is a standard regimen for patients with relapsed/refractory multiple myeloma (rrMM). With this regimen, only a small fraction of patients will achieve high quality responses [≥ very good partial response (VGPR)]. The combination of bendamustine (B), lenalidomide and dexamethasone (BRd) has shown high efficacy in patients with advanced rrMM. However, dose-limiting haematotoxicity restricted its use in extensively pre-treated patient populations. This prospective, multicentre Phase II study evaluated the efficacy and safety of BRd in rrMM patients with one prior line of therapy. Fifty patients were enrolled (median age 68·5 years [range 46-83]) and were treated with B 75 mg/m2 days 1, 2; R 25 mg days 1-21 and d (40/20 mg) days 1, 8, 15 and 22, for 6 28-day induction cycles, followed by 12 cycles with Rd alone. Pegfilgrastim was administered according to protocol-defined criteria. The study aimed to demonstrate a complete response (CR)/VGPR rate of >40% after induction therapy. Of 45 evaluable patients, 23 (51%) achieved a CR/VGPR. Grade 4 neutropenia or thrombocytopenia occurred in 17 (34%) and 8 (16%) of patients, respectively. BRd is a safe and efficacious regimen as a second line treatment for rrMM, leading to high quality responses in a considerable proportion of patients., (© 2016 John Wiley & Sons Ltd.)- Published
- 2017
- Full Text
- View/download PDF
5. Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
- Author
-
Knauf W, Abenhardt W, Dörfel S, Meyer D, Grugel R, Münz M, Hartmann H, and Marschner N
- Subjects
- Antibodies, Monoclonal, Murine-Derived administration & dosage, Bendamustine Hydrochloride, Chlorambucil administration & dosage, Cyclophosphamide administration & dosage, Female, Germany, Hematology methods, Hematology statistics & numerical data, Humans, Male, Nitrogen Mustard Compounds administration & dosage, Office Visits statistics & numerical data, Prednisone administration & dosage, Prospective Studies, Rituximab, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Registries statistics & numerical data
- Abstract
Various treatment options exist for patients with chronic lymphocytic leukaemia (CLL). Clinical registries provide insight into routine treatment and identify changes in treatment over time. The Tumour Registry Lymphatic Neoplasms prospectively collects data on the treatment of patients with lymphoid B-cell neoplasm as administered by office-based haematologists in Germany. Data on patient and tumour characteristics, co-morbidities, systemic treatments, and outcome parameters are recorded. Eight hundred and six patients with CLL were recruited between May 2009 and August 2013. At the start of first-line treatment, median age was 71 years, 64% were male, and 44% had a Binet stage C disease. The most frequently used first-line/second-line regimens were bendamustine + rituximab (BR, 56%/55%), fludarabine + cyclophosphamide + rituximab (FCR, 22%/11%), and bendamustine (B, 5%/9%). Chlorambucil was used in only 7% (first-line) and 6% (second-line) of patients. Patients treated with FCR were younger and healthier than patients treated with BR. Overall, 91% of first-line treatments were successful (40% complete response). Real-life patient populations differ considerably from patients treated in randomized controlled trials. BR and FCR dominate the first-line and second-line treatments of CLL by office-based haematologists in Germany. Future analysis will investigate progression-free and overall survival times., (© 2014 The Authors. Hematological Oncology Published by John Wiley & Sons, Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
6. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
- Author
-
Schmidt-Hieber M, Fietz T, Knauf W, Uharek L, Hopfenmüller W, Thiel E, and Blau IW
- Subjects
- Acute Disease, Adult, Basiliximab, Drug Tolerance, Feasibility Studies, Female, Follow-Up Studies, Hematologic Neoplasms surgery, Humans, Male, Middle Aged, Prospective Studies, Steroids therapeutic use, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Graft vs Host Disease drug therapy, Hematopoietic Stem Cell Transplantation mortality, Immunosuppressive Agents therapeutic use, Receptors, Interleukin-2 antagonists & inhibitors, Recombinant Fusion Proteins therapeutic use
- Abstract
Acute graft-versus-host disease (aGVHD) occurs in up to 80% of patients who undergo allogeneic stem cell transplantation (SCT) and contributes significantly to transplant-related mortality (TRM). We conducted a prospective phase II trial to assess the efficacy and feasibility of treating steroid-refractory aGVHD with basiliximab, a chimaeric monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor. Basiliximab was administered intravenously at a dose of 20 mg on days 1 and 4. Twenty-three patients were enrolled between October 1999 and July 2004. We found a primary overall response rate of 82.5% with four patients (17.5%) showing a complete response and 15 patients (65%) a partial response. Six patients were again treated successfully with an IL-2 receptor antagonist because of recurrence of aGVHD. The rates of infections, chronic GVHD, malignancy recurrence and 1-year TRM following immunosuppression with basiliximab were comparable with those found with other treatment modalities for aGVHD. We conclude that basiliximab is efficient and feasible for steroid-refractory aGVHD and merits further evaluation.
- Published
- 2005
- Full Text
- View/download PDF
7. Intramedullary abscess in a patient with disseminated Scedosporium apiospermum infection.
- Author
-
Fietz T, Knauf W, Schwartz S, and Thiel E
- Subjects
- Adult, Antifungal Agents therapeutic use, Dermatomycoses drug therapy, Drug Resistance, Fungal, Fatal Outcome, Humans, Immunocompromised Host, Male, Mycetoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Recurrence, Abscess complications, Dermatomycoses complications, Mycetoma complications, Opportunistic Infections complications, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Scedosporium
- Published
- 2003
- Full Text
- View/download PDF
8. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation.
- Author
-
Rojewski MT, Baldus C, Knauf W, Thiel E, and Schrezenmeier H
- Subjects
- Arsenic Trioxide, Cell Cycle drug effects, Cell Division drug effects, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Humans, Tumor Cells, Cultured, Antineoplastic Agents pharmacology, Apoptosis drug effects, Arsenicals pharmacology, Leukemia, Myeloid pathology, Oxides pharmacology
- Abstract
Clinical efficacy of As2O3 has been shown in patients with relapsed acute promyelocytic leukaemia (APL). There is evidence that the effects of As2O3 are not restricted to events specific for APL. As2O3 might target mechanisms involved in the pathogenesis of other malignancies. We assessed susceptibility to induction of apoptosis by As2O3 and cytostatics in 22 myeloid and non-myeloid malignant cell lines. As2O3 was used in concentrations of 0.01-10 micromol/l. Cell lines displayed different kinetics of response and different sensitivity to As2O3. The minimum concentration of As2O3 for induction of apoptosis was 0.1 micromol/l. High concentrations of As2O3 (5 micromol/l) induced apoptosis in a large proportion of cells in all cell lines tested. Low (1 micromol/l As2O3) concentrations induced apoptosis in NB-4, HL-60, U-937, CEM, HL-60, KG-1a, PBL-985, ML-2 and MV-4-11, but not in HEL, K-562, KG-1 and Jurkat up to 35 d of incubation. However, the non-apoptotic population of 1 micromol/l As2O3-treated HEL, K-562, K-562 (0.02), K-562(0.1) and Jurkat showed reduced proliferation. CEM as well as its' multidrug-resistant derivatives were sensitive to 1 micromol/l As2O3. In summary, these data demonstrate that As2O3-induced apoptosis is not restricted to cell lines with t(15;17). Apoptosis was induced in vitro by As2O3 concentrations that are achievable in vivo after infusion of well-tolerated As2O3 doses. Thus, As2O3 might be a suitable therapeutic agent for malignancies other than APL provided the adequate dose and duration of As2O3 treatment are used.
- Published
- 2002
- Full Text
- View/download PDF
9. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
- Author
-
Hallek M, Schmitt B, Wilhelm M, Busch R, Kröber A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Döhner H, Thiel E, Hiddemann W, Brittinger G, and Emmerich B
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Female, Humans, Leukopenia chemically induced, Male, Middle Aged, Neutropenia chemically induced, Thrombocytopenia chemically induced, Treatment Outcome, Vidarabine administration & dosage, Vidarabine adverse effects, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
- Abstract
The efficacy and toxicity of a combination of fludarabine and cyclophosphamide (FC) was evaluated in patients with B-cell chronic lymphocytic leukaemia (CLL). Between April 1997 and July 1998, 36 patients with CLL (median age 59 years) received a regimen that consisted of fludarabine 30 mg/m(2) in a 30-min IV infusion, d 1-3, and cyclophosphamide 250 mg/m(2) in a 30-min IV infusion on d 1-3. Cycles were repeated every 28 d. Twenty-one patients had received between one and three different treatment regimens prior to the study, while 15 patients had received no prior therapy. The median Eastern Cooperative Oncology Group performance score was 1. One patient was at Binet stage A, 18 were stage B and 17 patients were stage C. Objective responses, assessed according to the revised guidelines of the National Cancer Institute-sponsored Working Group, were recorded in 29 out of 32 assessable patients (90.6%). Twenty-four partial remissions and five complete remissions were observed. Two patients showed no change and one patient showed disease progression. At February 2000, three of the responders had relapsed. Severe neutropenia, anaemia and thrombocytopenia (Common Toxicity Criteria grade 3 and 4) were observed in 25, six and six patients (69.4%, 16.7% and 16.7%) respectively. Other side-effects were uncommon. No treatment-related deaths and no grade 3 or 4 infections occurred. We conclude that the combination of fludarabine and cyclophosphamide showed significant activity in patients with CLL. Myelosuppression was the major side-effect. These results warrant further study on the FC combination in randomized trials.
- Published
- 2001
- Full Text
- View/download PDF
10. CD82 (KAI1), a member of the tetraspan family, is expressed on early haemopoietic progenitor cells and up-regulated in distinct human leukaemias.
- Author
-
Burchert A, Notter M, Dietrich Menssen H, Schwartz S, Knauf W, Neubauer A, and Thiel E
- Subjects
- Antigens, CD34 metabolism, Cell Differentiation, Cell Transformation, Neoplastic, Humans, Kangai-1 Protein, Leukemia pathology, Tumor Cells, Cultured, Up-Regulation, Antigens, CD metabolism, Hematopoietic Stem Cells metabolism, Leukemia metabolism, Membrane Glycoproteins metabolism, Proto-Oncogene Proteins
- Abstract
CD82 (KAI1) is a member of the tetraspan transmembrane protein family which has been cloned from lymphoblastoid variant cell lines. However, a role for CD82 in early normal and malignant haemopoiesis has not yet been characterized. We studied the CD82 expression in 33 normal donor samples and 98 leukaemias by fluorescence activated cell sorting (FACS) and reverse transcriptase polymerase chain reaction (RT-PCR). We demonstrated that CD82 was moderately expressed in the vast majority of normal granulocytes and monocytes. In contrast, only about one third of the peripheral blood lymphocytes were weakly CD82 positive (CD82+). Interestingly, judgement of the CD82 transcription and expression in various leukaemias revealed that CD82 was overexpressed in chronic myeloid leukaemia (CML) patients in accelerated or blastic phase (CML-AP/BP) as well as in acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL) patients. Analysis of AML patients with CD34+/CD82+ blasts prompted us to expand our studies on haemopoietic CD34+ progenitor cells. Intriguingly, 84-95% of the CD34+ cells isolated from healthy bone marrow, cord blood or peripheral blood were highly CD82+. CD82 was abundantly expressed on primitive as well as on committed haemopoietic progenitor cells. After in vitro induction of myeloid differentiation in CD34+ peripheral blood progenitor cells (PBPC), the expression of CD82 decreased to levels similar to those found on peripheral blood granulocytes. These observations suggest for the first time a role for CD82 in normal and malignant haemopoiesis.
- Published
- 1999
- Full Text
- View/download PDF
11. Overexpanded B cell clone mediating leukemic arthritis by abundant secretion of interleukin-1beta: a case report.
- Author
-
Rudwaleit M, Elias F, Humaljoki T, Neure L, Knauf W, Stein H, Distler A, Sieper J, Berek C, and Braun J
- Subjects
- Amino Acid Sequence, Arthritis immunology, Arthritis pathology, B-Lymphocytes immunology, Base Sequence, Clone Cells metabolism, Cytokines metabolism, DNA Primers chemistry, DNA, Neoplasm analysis, Gene Rearrangement, Genes, Immunoglobulin genetics, Humans, Immunoenzyme Techniques, Leukemia, Lymphocytic, Chronic, B-Cell immunology, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Male, Middle Aged, Molecular Sequence Data, Synovial Membrane metabolism, Synovial Membrane pathology, Wrist Joint pathology, Arthritis metabolism, B-Lymphocytes metabolism, Interleukin-1 metabolism, Leukemia, Lymphocytic, Chronic, B-Cell metabolism
- Abstract
The role of cytokines in leukemic arthritis is unknown. The presentation of a patient with B cell chronic lymphocytic leukemia and destructive arthritis of the wrist joints prompted us to study the synovial cytokine pattern by immunohistologic analysis. In addition, rearranged V(H) and V(L) immunoglobulin genes were sequenced to assess B cell clonality. Heavy infiltrations of CD20+ cells with lambda light chain restriction were found in the synovial tissue. Sequencing demonstrated overexpansion of a single B cell clone (DP58/D/J(H)4b and IGLV3S2/Jlambda2-Jlambda3 for V(H) and V(L), respectively) in the peripheral blood. Identical V(H) and V(L) rearrangements were found in the synovial infiltrates. Somatic mutations were found in both the peripheral blood and the synovial clone. Immunohistologic study revealed the presence of abundant interleukin-1beta (IL-1beta) and, to a lesser degree, tumor necrosis factor beta (TNFbeta) (lymphotoxin). In contrast, TNFalpha, interferon-gamma, IL-4, IL-6, and IL-10 were rarely found in the synovial infiltrates. Therefore, IL-1beta secreted in great amounts by leukemic B cells appears to be the major cytokine that mediates joint destruction in leukemic arthritis.
- Published
- 1998
- Full Text
- View/download PDF
12. Interferon-alpha 2b (IFN alpha) for early-phase chronic lymphocytic leukaemia with high risk for disease progression: results of a randomized multicentre study.
- Author
-
Langenmayer I, Nerl C, Knauf W, Dempster S, Hallek M, Adorf D, Dietzfelbinger H, Busch R, Ziegler-Heitbrock HW, Thiel E, and Emmerich B
- Subjects
- Aged, Disease Progression, Disease-Free Survival, Female, Follow-Up Studies, Forecasting, Humans, Immunoglobulin A metabolism, Immunoglobulin G metabolism, Immunoglobulin M metabolism, Interferon alpha-2, Interferon-alpha adverse effects, Male, Middle Aged, Recombinant Proteins, Risk Factors, Interferon-alpha therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell therapy
- Abstract
The efficacy of interferon-alpha 2b (IFN alpha) to prolong progression-free (PFS) and/or overall survival (OS) in early B-CLL (Binet stage A) was examined in a risk-adapted phase III study. 99 previously untreated B-CLL patients were recruited. 44 patients with expected high risk for disease progression, defined by non-nodular bone marrow infiltration and lymphocyte doubling time < or = 12 months or serum thymidine kinase levels > or = 5 U/I, were randomized to either receive IFN alpha (group 1, n = 21) or not (group 2, n = 23). 55 low-risk patients were observed to evaluate this risk stratification (group 3). During a median observation time of 36 months, four patients in the IFN alpha group achieved a partial remission (PR), no patient had stable disease (SD), and 17 patients experienced progressive disease (PD). The four responders had less extensive disease at study entry and tended to exhibit a rise in serum IgG levels. In group 2, no PR, seven SD and 16 PD, whereas in group 3, no PR, 37 SD and 18 PD occurred. PFS in group 1 (6.7 months) was not different from group 2 (13.3 months, P = 0.22), but PFS of groups 1 and 2 differed from group 3 (37 months, P < or = 0.001). OS was 44.9 months (group 1), 43.1 months (group 2) and 57.9 months (group 3). OS was not significantly different for group 1 v 2, but was significant between groups 1 and 3 (P = 0.023). The higher percentage of PD in group 2 compared to group 3 (70% v 29%) shows that the selected risk factors allow the definition of CLL stage A patients at risk for disease progression within about a year. In conclusion, our data indicate that IFN alpha does not prolong PFS or OS in stage A CLL patients with high risk for disease progression.
- Published
- 1996
- Full Text
- View/download PDF
13. Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia.
- Author
-
Ho AD, Knauf W, Ganeshaguru K, Hunstein W, and Hoffbrand AV
- Subjects
- 5'-Nucleotidase, B-Lymphocytes, Humans, Adenosine Deaminase metabolism, Leukemia enzymology, Lymphoma enzymology, Neoplastic Cells, Circulating, Nucleoside Deaminases metabolism, Nucleotidases metabolism, Pentosyltransferases metabolism, Purine-Nucleoside Phosphorylase metabolism
- Abstract
Previous reports have shown that the purine degradative enzymes adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP) and ecto-5'-nucleotidase (5'NT), play an important role in the normal development of lymphocytes and that investigations of these enzymes are of value in defining subsets of lymphoid malignancies of T-cell origin. Pharmacological inhibition of one of these enzymes has been found to be an effective treatment for a few lymphatic neoplasia. We have studied the activities of the above enzymes in the circulating malignant cells of 25 patients with B-chronic lymphatic leukemia (B-CLL), four patients with B prolymphocytic leukemia (PLL), seven patients with leukemic centrocytic lymphoma (CC), 18 patients with hairy cell leukemia (HCL) and 16 patients with immunocytoma (IC). For comparison, the blasts of nine patients with 'common' acute lymphatic leukemia (cALL) and normal T (n = 12) and B (n = 8) cells were simultaneously investigated. Despite morphologic similarity, the leukemic cells of the chronic B cell malignancies demonstrate different enzyme patterns. B-CLL is characterized by very low activities of all the enzymes ADA, PNP and 5'NT. In the cells of HCL the highest values of PNP are found. The leukemic cells of IC are characterized by low levels of ADA but moderate levels of PNP and high levels of 5'NT. Thus some of the entities of B malignancies show typical enzyme patterns which might be of importance in defining maturation stages of the disease. The differences in these enzyme patterns can also be made use of in therapy with enzyme inhibitors such as deoxycoformycin.
- Published
- 1987
- Full Text
- View/download PDF
14. Magnetic resonance imaging of bone marrow in lymphoproliferative disorders: correlation with bone marrow biopsy.
- Author
-
Döhner H, Gückel F, Knauf W, Semmler W, van Kaick G, Ho AD, and Hunstein W
- Subjects
- Adult, Aged, Biopsy, Bone Marrow anatomy & histology, Clinical Trials as Topic, Hodgkin Disease pathology, Humans, Lymphoma, Non-Hodgkin pathology, Magnetic Resonance Spectroscopy, Male, Middle Aged, Prospective Studies, Bone Marrow pathology, Lymphoma diagnosis
- Abstract
In a prospective clinical study 10 normal volunteers and 30 patients with lymphoma--11 patients with Hodgkin's lymphoma and 19 patients with non-Hodgkin's lymphoma (11 low grade, 8 high grade)--were examined. Proximal femora, pelvis and lumbar spine were imaged with a 1.5 tesla superconducting MR imaging system (Siemens Magnetom). Areas of malignant infiltration in the bone marrow were clearly detected by visual and/or quantitative assessment. In most cases bone marrow involvement was demonstrated by both magnetic resonance imaging and bone marrow biopsies. However, in three of 30 patients magnetic resonance imaging showed evidence of lymphomatous involvement despite normal bone marrow histology. In one patient bone marrow cytology revealed malignant infiltration in the absence of MRI abnormalities. Thus, MRI is a sensitive method for detecting bone marrow infiltration by lymphoma.
- Published
- 1989
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.